Active RHOA favors retention of human hematopoietic stem/progenitor cells in their niche by Bithiah Jaganathan et al.
Jaganathan et al. Journal of Biomedical Science 2013, 20:66
http://www.jbiomedsci.com/content/20/1/66RESEARCH Open AccessActive RHOA favors retention of human
hematopoietic stem/progenitor cells in
their niche
Bithiah Grace Jaganathan1,2*, Fernando Anjos-Afonso1, Atul Kumar2 and Dominique Bonnet1*Abstract
Background: Hematopoietic stem/progenitor cells (HSPCs) maintain the hematopoietic system by balancing their
self-renewal and differentiation events. Hematopoietic stem cells also migrate to various sites and interact with their
specific microenvironment to maintain the integrity of the system. Rho GTPases have been found to control the
migration of hematopoietic cells and other cell types. Although the role of RAC1, RAC2 and CDC42 has been
studied, the role of RHOA in human hematopoietic stem cells is unclear.
Results: By utilizing constitutively active and dominant negative RHOA, we show that RHOA negatively regulates
both in vitro and in vivo migration and dominant negative RHOA significantly increased the migration potential of
human HSC/HPCs. Active RHOA expression favors the retention of hematopoietic stem/progenitor cells in the niche
rather than migration and was found to lock the cells in the G0 cell cycle phase thereby affecting their long-term
self-renewal potential.
Conclusion: The current study demonstrates that down-regulation of RHOA might be used to facilitate the
migration and homing of hematopoietic stem cells without affecting their long-term repopulating ability. This
might be of interest especially for increasing the homing of ex vivo expanded HSPC.
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Hematopoietic stem cells maintain the hematopoietic
system through their proliferation, differentiation and
migration from their niche. These processes are regu-
lated at several levels and dysregulation was found to
lead to pathological conditions. Of many factors that
were found to control the migration, proliferation and
the self-renewal capacity of stem cells, Rho GTPases also
play an essential role. Rho GTPases belong to the Ras
superfamily of GTPases. They are involved in the
migration of different cell types, tumour cells and also in
the differentiation of mesenchymal stromal cells [1-7].
Rho GTPases act as molecular switches that cycle be-
tween active GTP-bound state and inactive GDP-bound
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article, unless otherwise stated.nucleotide Exchange factor (GEFs) and GTPase-activating
proteins (GAPs) [8,9]. Dysregulation of Rho GTPases was
associated with neutrophil dysfunction, leukemia, and
Fanconi anemia [10-12].
Enhanced activity of Rho GTPases was found to be as-
sociated with diverse hematologic abnormalities and ma-
lignancies [13-16]. Rac and Cdc42 have been found to
be up-regulated in human AML [17,18]. Rac1, one of
the members of the RhoGTPase family was shown to
regulate the homing of hematopoietic stem cells through
CXCR4/SDF1 signalling [19]. Rac1 was also found to be
important for homing and engraftment of HSC into the
BM niche and deficiency of Rac1 resulted in low engraft-
ment rates [19]. Hematopoiesis was also found to be
affected in Rac1 deficient embryo which is correlated
with the impaired response to CXCL12 stimulation [20].
Hematopoietic specific Rac2 was found to be important
for HSPC migration and adhesion and lack of Rac2
resulted in increased number of circulating HSPC. This
suggests that Rac2 is essential for stem cell adhesion tontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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these activities via the modulation of Rac1 and Cdc42
[22]. In addition, Rac2 mutation in hematopoietic cells
resulted in severe neutrophilia [23,24] and decreased
Cdc42 resulted in defective homing in Fanconi
anemia [25]. Cdc42 was also found to regulate HSC
migration and their retention in the hematopoietic
stem cell niche. Mice lacking Cdc42 showed increased
number of circulating HSC, rapidly cycling cells with
deficiency in directional migration and adhesion [26].
Cdc42 activity also drastically affected the actin
organization and cell adhesion. The increase in cyc-
ling of the cells was found to be mediated by p21CIP1
and c-Myc [26].
Although the role of Rac1, Rac2 and Cdc42 in
hematopoiesis is well studied, function of RhoA is
still not clearly understood. Our current study and
other reports indicate that RhoA function seems to
be cell type specific and species specific. In mice, in-
hibition of RhoA by dominant negative RhoAN19 re-
duced the migration of HSPCs but increased their
engraftment [27]. However, the role of RhoA on hu-
man hematopoietic stem cell function, migration, and
engraftment is still unclear.
Our studies in human cells show that RHOA inhib-
ition increased the chemotactic migration of HSPCs
without affecting their engraftment potential. We report
here for the first time that RHOA expression favors
retention of HSPCs in the niche rather than inducing
their migration. Furthermore, inhibition of RHOA sig-
nificantly increased the in vivo BM migration and
homing of human HSPCs in mice without affecting their
engraftment levels.Methods
Isolation of lineage depleted cord blood mononuclear
cells (HSPCs)
Umbilical cord blood was obtained after informed consent
from the Royal London Hospital, London, UK in accord-
ance with the local Research Ethics Committees guide-
lines. The mononuclear cells were separated by density
gradient centrifugation and enriched for progenitor cells
using human progenitor enrichment cocktail and Stem
Sep column (Stem Cell Technologies, Vancouver, Canada).
The resulting lineage depleted mononuclear cells (CBLin-)
termed as Hematopoietic stem/Progenitor cells (HSPCs)
were used for further experiments.Real-time PCR
Quantitative real-time PCR was performed on sub-
fractions of the hematopoietic cells to quantify the tran-
script level of Rho GTPases RHOA. Total cellular RNA
was extracted using RNeasy kit (Qiagen, Crawley, UK)and reverse transcribed into cDNA with Superscript III
reverse transcriptase (Invitrogen). Real-time PCR was
performed with SYBR-Green (ABI Biosystems, Carlsbad,
USA) in an ABI 7900HT (ABI Biosystems) real-time
PCR machine. The specificity of the product was veri-
fied in a 2% agarose gel. The primers used were:
RHOA forward 5′-CTGGTGATTGTTGGTGATGG-
3′ and RHOA reverse 5′-GCGATCATAATCTTCCTG
CC-3′[28] and GAPDH forward 5′- GGGAAGGTGA
AGGTCGGAGT-3′ and GAPDH reverse 5′- GGGT
CATTGATGGCAACAATA-3′.Lentiviral vectors
The lentiviral vectors used for the study were based on
pHRcPPT SIEW Sin vector with IRES regulating eGFP
reporter gene. The vector contains SFFV (Spleen Focus
Forming Virus)-LTR promoter and WPRE (Woodchuck
Hepatitis Virus) element for post-transcriptional pro-
cessing. RHOA constitutively active (RHOAV14) and
dominant negative (RHOAN19) sequences were cloned
from pBluescript vectors (kindly provided by Dr. Michael
Way, Cancer Research UK, London, UK) by PCR using
the primers F: 5′-GCGCGGATCCATGGCTGCCATCC
GGAA-3′; R: 5′-GCGCGGATCCTCACAAGACAAGGC
AAC-3′. The sequences were cloned into Topo Cloning
vector (Invitrogen, Paisley, UK) and subcloned subse-
quently into SIEW by BamHI digestion. The orientation
and the presence of mutation were confirmed by DNA
sequencing. Lentiviral vector with only IRES GFP was
used as experimental control.Lentiviral production and concentration
Lentiviral particles were generated by transfecting the
transfer plasmid into 293 T cells with the packaging
plasmids pCMVR8.94 and envelope pMD.G as de-
scribed previously [3]. Viral supernatants were col-
lected 48 and 72 hr after transfection and concentrated
by ultracentrifugation.Lentiviral transduction of lineage depleted cord blood
mononuclear cells
Freshly isolated or frozen lineage depleted mononuclear
cells were stimulated for 8 hr with cytokines hFlt3L
(50 ng/ml), hSCF (50 ng/ml), hIL-6 (10 ng/ml) and
hTPO (20 ng/ml). After stimulation, transduction of
HSPC cells were performed by the addition of the lenti-
virus particles containing control, RHOAV14 and
RHOAN19 at a multiplicity of infection (M.O.I) of 80 in
the presence of polybrene (4 μg/ml). Sixteen hours after
transduction, the cells were washed and used for further
experiments.
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CFU-C assay was performed for cells transduced with
RHOA constructs in methylcellulose medium (Methocult
H4434, Stem Cell Tech, Vancouver, Canada). Briefly, 1 ×
103 cells were seeded in 35 mm culture dishes and incu-
bated at 37°C, 5% CO2. GFP positive cell aggregates of
more than 50 cells were counted as colonies at 14 days in
an inverted fluorescent microscope (Leica, Switzerland)
according to the colony morphology. Long-term culture-
initiating cell assay (LTC-IC) was performed by plating 1 ×
104 transduced cells on a monolayer of irradiated M2-10B4
cells and half-media replaced every 7 days. At the end of
5 weeks, the cells were collected, plated in methylcellulose
medium for CFU-C assay and scored after 14 days. Liquid
culture was performed to maintain the cells in progenitor
stage by seeding the cells in serum free medium (Stem Cell
Tech) containing hSCF (300 ng/ml), hFlt3L (300 ng/ml)
and hTPO (20 ng/ml)and fresh media was added every 2–
3 days.
In vitro transwell migration assay
Cord blood lineage depleted cells (HSPCs) were transduced
with control, constitutively active RHOA (RHOAV14) or
dominant negative RHOA (RHOAN19) and cultured in
serum free medium supplemented with hSCF (300 ng/ml),
hFLT3L (300 ng/ml) and hTPO (20 ng/ml) for 7 days.
Cytokines were added every 2–3 days. 100,000 cells were
seeded in the transwell chambers (5 μm pore size) coated
with fibronectin. SDF1α was added to the lower well
(125 ng/ml) and the cells were allowed to migrate for
4 hours. The migrated cells in the lower well was collected
and enumerated by flow cytometry (LSR II, Becton
Dickinson) with the counting beads (Molecular Probes).
Phenotype and cell cycle analysis
The transduced cells were identified by their expression of
the reporter gene eGFP. Cell surface markers expression
was determined by staining the cells with fluorescent conju-
gated antibodies and analyzed by flow cytometry. Cell cycle
analysis was performed by fixing the cells with 2% parafor-
maldehyde and permeabilised with 0.1% Triton X-100. The
cells were stained with anti-Ki67 conjugated with Alexa647
(Molecular Probes) and resuspended in 2% FCS containing
DAPI (4′, 6-diamidino-2-phenylindole) and analyzed by
flow cytometry.
Short-term homing experiment
RHOA transduced HSPC cells were expanded in serum
free media containing stem cell factor (SCF, 300 ng/ml),
FMS likle tyrose kinase ligand (FLT3L, 300 ng/ml) and
thrombopoietin (TPO, 20 ng/ml) for one week with
addition of growth factors every second day. The cells
were washed and 0.5 × 105 transduced cells were injected
intravenously in NOD/SCID/β2 mice. Bone marrowhoming was analysed 24 hours post-injection by staining
the bone marrow cells with antibodies against human
CD45.
In vivo migration and xeno-transplantation assay
All in vivo experiments were performed in accordance
with the UK Home Office regulations and Cancer Re-
search UK guidelines. NOD/SCID/β2 microglobulin null
mice were purchased from Charles River Laboratories,
UK. Mice aged 8–12 weeks were irradiated sub-lethally
with an irradiation dose of 375 cGy from a 137Cs source.
For migration experiments, 0.1 × 105 transduced HSPCs
cells were injected intra-bone into one of the hind limbs
of the mice. Bones from each limb was collected separ-
ately after 7–8 weeks and analyzed for human cell en-
graftment by staining with antibodies against human
CD45. For engraftment experiments, mice were intra-
venously injected with 0.5 – 1 × 105 transduced HSPCs.
The animals were sacrificed 12 weeks after transplant-
ation, femurs and tibiae were collected and the cells
were flushed and analyzed for human engraftment by
flow cytometry.
Statistical analysis
Statistical analysis was performed using One-way
ANOVA test (SPSS software) and statistical significance
in in vivo experiments were assessed using generalized
linear models based on the negative binomial distribu-
tion (R software).
Results
Reduced RHOA levels in HSPC population
In order to understand the role of RHOA in maintaining
the proliferation, migration and repopulating abilities of
human hematopoietic stem/progenitor cells (HSPCs), we
studied the expression of RHOA in CD34+CD38- and
CD34+CD38+ sub-fractions. Human cord blood derived
mononuclear cells were sorted into hematopoietic stem
and progenitor sub-populations based on markers such
as CD34, CD38 and lineage markers. The mRNA level
of RHOA in these fractions was determined by real-time
quantitative PCR. RHOA expression could be found in
CD34+CD38- stem cell population and the level de-
creases as they start to differentiate into CD34+CD38+
progenitor cells (Figure 1A).
Dominant negative RHOA increases HSPC migration
To analyze the effect of RHOA on hematopoietic cells,
HSPCs were lentivirally transduced with constitutively
active RHOA (RHOAV14), dominant negative RHOA
(RHOAN19) and the control vector. The lentivirus used
has an SFFV promoter expressing EGFP driven by IRES
(Figure 1B). RHOA genes were cloned between the SFFV
promoter and the IRES sequence. We found that
Figure 1 RHOA endogenous and exogenous expression. (A) Real-time PCR analysis to determine the mRNA levels of RHOA in lineage
depleted cord blood hematopoietic sub populations CD34+CD38- and CD34+CD38+ showed that RHOA was expressed in both the populations
and it was significantly higher in CD34+CD38- stem cell population. (B) Replication incompetent lentiviral vectors expressing RHOAV14 or
RHOAN19 with SFFV (Spleen focus forming virus) promoter with EGFP (enhanced Green fluorescent protein) driven by IRES (Internal Ribosome
Entry Site).
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whereas RHOAN19 expression effectively reduced the
active RHOA level in the transduced cells.
To determine the effect of RHOA on the migration of
HSPCs, RHOA transduced HSPCs were allowed to
migrate in a transwell chamber towards SDF1α gradient.
Post-migration analysis showed that there was a
significant increase in the percentage of migration of
RHOAN19 cells compared to the control group (35.5 ±
1.2% versus 18.6 ± 2.7%, p < 0.001) as shown in Figure 2A.
Although increase in migration in HSPCs during RHOA
down-regulation has been reported [2], there were no
reports to suggest its role in in vivo migration. We hy-
pothesized that decreased level of RHOA might also in-
crease the homing and migration in vivo. To confirm
this, we intravenously injected RHOA modified HSPCs
into mice and determined the percentage of human
(hCD45+ cells) present in the bone marrow 24 hours
post-injection. We found that there was a significant
increase in homing of HSPCs expressing RHOAN19 in
the bone marrow compared to the control group
(10.9 ± 2.7% in RHOAN19 versus 2.0 ± 1.9%, p = 0.0003,
Figure 2B). No significant effect was observed when the
constitutively active form RHOAV14 was over expressed
in HSPCs (Figure 2A and B) probably due to a compen-
satory mechanism.
Active RHOA favors retention in niche
To further confirm this and also to investigate the in-
volvement of RHOA in adhesion and migration of HSPC
in their niche, RHOA modified HSPCs were injected
intra-bone in the right femur of the mice (injected bone)
and the percentage of human CD45+ cells present in the
non-injected femur was determined by flow cytometry 7
to 8 weeks post-transplant. We found that the percent-
age of engraftment was similar in all three groups
(Figure 2D, control versus RHOAV14, p = 0.9585 and
control versus RHOAN19, p = 0.284). However therewas a 26% increase in the migration of RHOAN19
HSPCs from the injected (right) to the non-injected
(left) femur of the mice compared to the control
(Figure 2C), and there was a significant reduction in
the migration of RHOAV14 expressing HSPC (Figure
2C, 21.10 ± 9.89% in control versus 6.46 ± 3.03% in
RHOAV14, p = 0.039). To gain insight into the potential
reason for changes in migration/homing potential of
RHOA modified HSPC, we analyzed few adhesion mole-
cules involved in the migration/homing. The integrin
VLA-4 and VLA-5 expression was found to be similar in
all cases (data not shown) however there was a signifi-
cant increase in the expression of CD62L in RHOAV14
HSPCs compared to control cells (Figure 3A and B,
12.9 ± 1.4% in RHOAV14 cells versus 22.3 ± 3.1% in con-
trol cells, p = 0.009) but no decrease in the RHOAV19
HSPC group.
Active RHOA decreases HSPC proliferation
Since RHO GTPases have been found to control the cell
cycle of non-hematopoietic cells, we studied the effect of
RHOAV14 and RHOAN19 expression on the cell cycle
status of HSPCs. Even after stimulation with cytokines, 5
fold more cells were found to be in G0 phase of the cell
cycle in RHOAV14 expressing HSPC compared to
control (Figure 3C, and D). No change in cell cycle was
observed by expressing the constitutively dominant
negative form (RHOAV19). To better understand if the
difference in the cell cycle profile could affect the colony
forming ability, we performed a CFU-C assay. No differ-
ence in the colony forming capacity of RHOAV14 HSPC
was seen compared to control whereas a significant in-
crease in colony number was observed in RHOAN19
group (Figure 4A). In order to evaluate the long-term ef-
fect of the modulation of RHOA, long-term culture initi-
ating cells assay was performed. The number of colonies
after LTC was reduced significantly in the RHOAV14
group whereas a significant increase was observed in the
Figure 2 In vitro and in vivo migration: (A) Migration of HSPC in vitro: Transduced HSPC were seeded onto the upper well of the
transwell chamber and allowed to migrate towards SDF1α for 4 hours. The percentage of cells migrated toward a gradient of SDF1α were
calculated based on the absolute number of cells recovered in the lower chamber of transwell with respect to the total cells seeded. Values are
mean ± SD, n = 4. (B) Short-term homing of RHOA modified HSPC: Transduced HSPCs were expanded in a liquid culture for 7 days containing
cytokines. The cells were injected intravenously into NOD/SCIDβ2 microglobulin null mice and bone marrow was collected 24 hours post
injection and the percentage homing was analyzed. Values are normalized to the control, Mean ± SEM, n = 3. (C) In vivo migration of RHOA
modified HSPC: HSPC were transduced with active RHOA (RHOAV14) and dominant negative RHOA (RHOAN19) after stimulation with the
cytokines for 8 hours. 24 hours after transduction, the cells were injected intra-bone into the right femur of the NOD/SCIDβ2 microglobulin null
mice. Mice were sacrificed 7 weeks after injection, the left and right femur were collected separately. The percentage of engraftment in the right
femur and left femur were analyzed separately by staining for human CD45 and GFP expression and the percentage of migration from right to
the left femur were calculated. Values were normalized to the percentage of engraftment, mean ± SEM, n = 4-5. (D) Long-term engraftment of
RHOA modified HPC was analyzed in a NOD/SCIDβ2 microglobulin null mice 7 weeks post intra-bone injection. Values are Mean ± SEM, n = 4-5.
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that upon RHOAV14 expreession, the long-term but not
the short-term colony forming ability of HSPCs was
affected. To evaluate the in vivo effects of RHOA modu-
lation, xeno-transplantation assay was performed. After
7–12 weeks post transplantation the percentage of en-
graftment in RHOA modified cells (RHOAV14 and
RHOAN19) was comparable to the control group
(Figure 5A). There was a significant reduction in the per-
centage of human CD34 positive cells in the RHOAV14
group compared to control (Figure 5B) implying that
constitutively active RHOA significantly impede with the
proliferation of HSPCs in vivo.Taken together, these findings suggest that RHOA
negatively regulates in vitro chemotactic and in vivo mi-
gration of human HSPCs and RHOA seems to favor the
retention of HSPC in the niche rather than their migra-
tion. Active RHOA significantly reduced the prolifera-
tion of the HSPC in vivo.
Discussion
Hematopoietic stem cell proliferation, self-renewal,
differentiation and migration are controlled by various
factors and stimuli. HSC migration to the bone marrow
and its differentiation is essential to improve the
HSC engraftment during transplantation therapy. Earlier
Figure 3 Expression of CD62L and cell cycle. (A) Flow cytometry analysis of CD62L expression in control, RHOAV14 and RHOAN19 HSPCs. Plots are
a representative of at least 3 independent experiments. (B) RHOA transduced HSPCs were analyzed for their cell surface CD62L expression. Values are
mean ± SD, n = 3 independent experiments. (C) RHOA modified HSPCs were cultured in liquid culture in the presence of cytokines and at day 7 were
analyzed for their cell cycle profile using Ki-67 and DAPI. Plots are a representation of at least 3 independent experiments. (D) Graph representing the G0
percentage of control, RHOAV14 and RHOAN19 HPC/HSCs after 7 days in liquid culture. Values are Mean ± SD, n = 3 independent experiments.
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Cdc42 control various aspects of migration, differenti-
ation and self-renewal capabilities of murine HSPC but
the role of RHOA in human hematopoiesis has not been
investigated [19,21,22]. To understand the role of RHOAFigure 4 Long and short term colony forming ability assay. (A) Graph
assay when control, RHOAV14 and RHOAN19 cells were seeded in methylc
and RHOAN19 HSPC were maintained in a long-term culture (LTC-IC)for 5 w
CFU-C assay. Number of colonies obtained per 10,000 cells are shown, valuin human HSPCs, we modulated the active RHOA level
in HSPCs through constitutively active and dominant
negative forms. Transcript analysis of endogenous
RHOA expression in the stem and progenitor cell
population showed that RHOA was expressed in bothshowing the number of colonies obtained per condition in a CFU-C
ellulose medium. Values are mean ± SD, n = 3; (B) Control, RHOAV14
eeks and the colony forming ability was identified thereafter in a
es are mean ± SD, n = 3.
Figure 5 Long term repopulation of RHOA modified HSPC. (A) Percentage of human engraftment in Control, RHOAV14 and RHOAN19
expressing HSPCs, 12 weeks post-transplantation in immuno-deficient mice. Values are means ± SEM, n = 3. (B) Percentage of Human CD34
expression in Control, RHOAV14, RHOAN19 HSPCs 12 weeks post-transplantation. The percentage of CD34 expression was normalized to the
percentage of engraftment. Each dot in the graph represents individual mouse and the bar represents the median value.
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(CD34+CD38+) populations. In the present study, we
show that decreased RHOA activity through dominant
negative RHOA expression resulted in significantly in-
creased in vitro migration through SDF1α stimuli and
in in vivo migration and homing. We found a 2-fold in-
crease in the migration of HSPC from the injected
bone to the non-injected bone in xeno-transplantation
assay. As previously reported in human HSPCs by Bug
et al. [2] and in MSC by Jaganathan et al. [3], our
present study suggests that decreased RHOA activity is
essential for migration in human HSPCs both in vitro
and in vivo. Our observations are in contrast with the
results reported recently, where RhoAN19 expression
resulted in the decrease of SDF1α induced migration in
murine HSPCs [27]. In addition, the increase in RHOA
level through RHOAV14 expression resulted in an in-
crease in the retention of HSPCs in BM niche and a
decreased migration to the contra-lateral non-injected
bone in an in vivo migration assay although no differ-
ence in the engraftment percentage was seen. Our data
goes along with an earlier report suggesting that mi-
gration and engraftment of HSPCs occurs as separate
events in vivo [29] and thus might not always correlate
together as suggested [30].
The cell cycle control by Rho GTPases has been docu-
mented well in hematopoietic progenitor cells, cancer
cells and fibroblasts [27,31-34]. In murine hematopoietic
cells, RhoAN19 expression resulted in decreased levels
of P21Kip1/Waf1 and a higher number of cells in S
phase [27]. Although we did not find any changes in the
cell cycle profile when RHOAN19 was expressed in
human HSPCs under cytokine induction, there was a
significant increase in the number of colonies obtained
in short-term and long-term colony forming assays,which shows that RHOA controls the proliferation of
these cells. In addition, RHOAV14 expression in human
HSPCs locked the cells in G0 phase of the cell cycle
even under cytokine stimulation and reduced their
long-term but not short-term colony forming ability or
in vivo repopulating ability. Nevertheless, despite the
non-significant effect on the 7 to 10 weeks long-term re-
population in vivo, we observed a significant decrease in
the percentage of CD34+cells in the mice transplanted
with RHOAV14, providing some evidence that RHOA
negatively regulates the HSPC self-renewal but does not
inhibit the progenitor cell proliferation. Studies using
secondary transplantation should be performed to fur-
ther confirm these data.
Conclusions
In conclusion, we show that an active form of RHOA in
human HSPCs reduces the in vitro and in vivo migration,
bone marrow homing and lock the cells in G0 stage of the
cell cycle, favoring the retention of the cells in the niche. In
contrast RHOAN19 expression resulted in an increase in
migration and in the short-term and long-term colony
forming abilities without altering the cell cycle or the re-
populating ability of these cells. Thus, down-regulation of
RHOA might be used to facilitate the migration, homing of
hematopoietic stem cells without affecting their long-term
repopulating ability. This might be of interest especially for
increasing the homing of ex vivo expanded HSPC.
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